Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • AstraZeneca scores win...

    AstraZeneca scores win in race to treat ovarian cancer

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-08-19T15:45:09+05:30  |  Updated On 19 Aug 2019 3:45 PM IST
    AstraZeneca scores win in race to treat ovarian cancer

    Astra said its Lynparza drug, which blocks cancer's ability to repair its genetic code during cell division, was shown to slow the progression of ovarian cancer that has started to spread in the body.


    FRANKFURT: AstraZeneca has made further headway in the race with larger competitor GlaxoSmithKline's to use a promising new class of drugs to treat ovarian cancer.


    Astra said on Wednesday its Lynparza drug, which blocks cancer's ability to repair its genetic code during cell division, was shown to slow the progression of ovarian cancer that has started to spread in the body.


    The patient group that was examined in the so-called Paola-1 trial had been successfully given chemotherapy and Roche's Avastin as initial treatment following a diagnosis of advanced ovarian cancer.


    Those patients then normally receive Avastin as maintenance therapy to reinforce the initial regime and the study's aim was to show an advantage of adding Lynparza during the follow-up phase.


    Read Also: Daiichi Sankyo CEO capped USD 37 billion recovery with AstraZeneca deal: Bloomberg


    Lynparza, part of a class of drugs known as PARP inhibitors, is already approved as maintenance therapy in a different ovarian-cancer patient group that has received chemotherapy alone as initial treatment.


    Domestic rival GSK's Zejula, also a PARP inhibitor, last month showed promise in a similar treatment setting.


    Astra said detailed trial results would be presented at a medical conference which the company did not specify.


    Read Also: Patent Infringement: AstraZeneca moves US court against Dr Reddy’s on generic version of blockbuster Brilinta

    AstraZenecaAvastincancerchemotherapyGlaxoSmithKlineGSKLynparzaovarian cancerPaola-1PARP inhibitorspharmapharma companypharma newsRoche
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok